Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2015

Liu Y, Huang X, He X, Zhou Y, Jiang X, Chen-Kiang S, et al. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function. FASEB J. 2015;29(12):4829-39.

Correction to Supporting Information for Talantova et al., Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci U S A. 2015;112(28):E3751-2.

Kiuru M, Camp B, Adhami K, Jacob V, Magro C, Wildman H. Treatment of metastatic cutaneous Crohn disease with certolizumab. Dermatol Online J. 2015;21(11).

Kim D-, Hwang I, Muller FL, Paik J-. Functional regulation of FoxO1 in neural stem cell differentiation. Cell Death Differ. 2015;22(12):2034-45.

Khani F, Epstein JI. Prostate Biopsy Specimens With Gleason 3+3=6 and Intraductal Carcinoma: Radical Prostatectomy Findings and Clinical Outcomes. Am J Surg Pathol. 2015;39(10):1383-9.

Hannah J, Zhou P. Methods: A small-molecule SMASh hit. Nat Chem Biol. 2015;11(9):637-8.

Crescenzo R, Inghirami G. Anaplastic lymphoma kinase inhibitors. Curr Opin Pharmacol. 2015;23:39-44.

Niesvizky R, Badros AZ, Costa LJ, Ely SA, Singhal SB, Stadtmauer EA, et al. Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Leuk Lymphoma. 2015;56(12):3320-8.

Yang C, Boyson CA, Di Liberto M, Huang X, Hannah J, Dorn DC, et al. CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity. Cancer Res. 2015;75(9):1838-45.

Boysen G, Barbieri CE, Prandi D, Blattner M, Chae S-, Dahija A, et al. SPOP mutation leads to genomic instability in prostate cancer. Elife. 2015;4.